Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2019 21:00 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Outlines 2019 Key Milestones

BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its...
December 03, 2018 07:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy;U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9...
November 30, 2018 09:00 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

BURNABY, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call...
November 07, 2018 16:02 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

BURNABY, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's...
November 06, 2018 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Xenon...
October 30, 2018 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update

BURNABY, British Columbia, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third...
September 17, 2018 16:15 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares

BURNABY, British Columbia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the closing of...
September 12, 2018 20:15 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares

BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the pricing of...
September 12, 2018 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced that it has...
September 10, 2018 21:17 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program

BURNABY, British Columbia, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced it has signed...